More interestingly, the induction effect of HDAC inhibitors on CYP1A2 promoter was much more robust in cancer cells (Hep3B, PCL/PRF/5, Huh7, H1299, MCF7) than that in non-tumorigenic cell lines (MIHA, LO2, 293T) and the strongest induction was observed in HCC cells Hep3B, PCL/PRF/5 and Huh7 “Fig 5B”. Here, HDAC9 is linked to hepatocellular carcinoma.